triazolam + TS-172

triazolam + TS-172 is an experimental combination of triazolam, a short-acting benzodiazepine hypnotic used for the short-term treatment of insomnia, and TS-172, an orally administered investigational agent in development for the treatment of hyperphosphatemia, particularly in patients with chronic kidney disease on hemodialysis. Triazolam acts through positive allosteric modulation at the GABA-A receptor, enhancing inhibitory neurotransmission in the central nervous system. The exact mechanism of action of TS-172 remains undefined, but it is classified under hyperphosphatemia therapies, likely functioning as a phosphate binder or modulator of phosphate metabolism. This combination is primarily being studied in drug-drug interaction trials to assess mutual effects on pharmacokinetics, safety, and tolerability in healthy adults, with a focus on the interaction of triazolam (a CYP3A substrate) and TS-172.

Other names

triazolam + TS-172